Also found in: Medical, Wikipedia.
MDM2Mouse Double Minute 2
MDM2Murine Double Minute 2 Gene (pathology)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
We may soon be able to test for MDM2 amplification allowing prediction whether particular patients are at greater risk of hyperprogression on these immunotherapy treatments.
It has been reported that the level and activity of p53 are strictly modulated by the ubiquitin E3 ligase Mdm2, which binds p53 directly and mediates p53 ubiquitination and proteasomal degradation continuously (21).
IDH1 Ivosidenib Approved Adults with relapsed or refractory AML associated with IDH1 mutation FT-2102 and others Investigational BCL2 Venetoclax Investigational TET2 Vitamin C and Approved (*) AML with low blast count (*) hypomethylating agents CD33 Gemtuzumab ozogamicin Approved Newly diagnosed CD33-positive AML MDM2 Idasanutlin Investigational (*) US Food and Drug Administration (FDA) approval status (#) Hypomethylating agent (azacitidine) approved for low blast count AML in the US
The LIG_MDM2 motifs corresponded with amino acid residues FSFLWRGL (253-260) functional residues of p53 family members, which shows binding to the N-terminal domain of the MDM2 protein in the nucleus.
The keys to diagnosing myofibroblastic DL in the absence of finding a well-differentiated liposarcomatous component are identifying enlarged cells with pleomorphic nuclei (which may be scattered), atypical mitotic figures, and MDM2 amplification or overexpression.
Another targeted therapy in dedifferentiated liposarcoma subtype is the significant presence of the MDM2 gene.
Mouse double minute 2 (MDM2) is an oncoprotein that acts as a negative regulator inhibiting p53 tumor suppressor activity.
To our knowledge, there is no study in the literature comparing the accuracy of MRI diagnosis to the new gold standard for pathologic diagnosis, MDM2. Therefore, the purpose of this study is (1) to evaluate the ability of experienced readers of MR imaging to distinguish between lipoma and ALT/WDLs in the era of MDM2 FISH, (2) to evaluate the agreement of MRI interpretations amongst experienced readers, (3) to evaluate the utility of the diagnostic formula proposed by Wang et al., and to determine whether or not it is able to outperform the interpretation of fellowship-trained readers, and (4) to determine which MRI characteristics, if any, are most predictive of the diagnosis of ALT/WDLs.
For example, the parameter values associated with FOXO3a are taken from proteins that have a similar function to FOXO3a, such as MDM2. It could be very useful for determining reasonable ranges for the rate of various biochemical reactions involved.
MDM2 is an oncogene, the amplification and overexpression of which are linked to progression and poor prognosis of different cancers.
Under normal conditions, p53 level is low as a result of rapid proteolysis: p53 is inactivated by mouse double minute 2 homolog (MDM2), which enhances the degradation of p53 by proteasomes.
Positive staining for MDM2 (Figures 3(b), 3(d), and 3(f)) and CDK4 (data not shown) by immunohistochemistry and negativity of DDIT3 or FUS by FISH (data not shown) confirmed dedifferentiated liposarcoma.